P15-15. Advocates' perspectives on community engagement in the HVTN 505 by Warren, M et al.
BioMed  Central
Page 1 of 1
(page number not for citation purposes)
Retrovirology
Open Access Poster presentation
P15-15. Advocates' perspectives on community engagement in the 
HVTN 505
M Warren*, E Bass, C Feuer, K Fisher, D Grant and L Miller
Address: AIDS Vaccine Advocacy Coalition, New York, USA
* Corresponding author    
Background
In September of 2007, the trial of Merck's MRK-Ad5 AIDS
vaccine candidate came suddenly and unexpectedly to a
halt. Results suggesting enhanced susceptibility to HIV
infection in certain trial participants placed the planned
PAVE 100 trial of the Vaccine Research Center's DNA
prime/Ad5-vectored boost vaccine strategy into question.
At the same time, the Step trial analysis suggested that
some vaccines might have benefited from lower viral
loads post infection. A year after Step ended, NIAID
announced that it was considering a smaller trial of the
VRC's strategy, which became HVTN 505 – no longer
PAVE 100.
Methods
Since the Step results were announced, AVAC and its part-
ners have engaged in numerous structured conversations
with NIAID, its Vaccine Research Program, CABs and the
broader community of HIV prevention advocates like
AVAC who are not part of trial site communities. This
work has provided a documented case history of how
community engagement has functioned within the con-
text of both the Step trial and proposed trials of the VRC
candidate.
Results
The Step results brought an unprecedented dialogue
between the trial sponsors and civil society. There was a
high level of information and materials sharing and con-
structive dialogue around crafting messages that were
accurate and moved the field ahead. This held true around
PAVE 100 as well. But with the advent of 505, the gap has
increased between the broader community and the trial
sponsors, which has impeded community stakeholders
from getting involved.
Conclusion
HVTN 505 will likely be one of the most complex trials to
explain and in which to enroll participants, making the
collaborative work that should be in place for any trial
critically important. Community participation and
engagement in Step made important progress toward inte-
gration into clinical trial development and support. The
success of HVTN505 depends upon building and expand-
ing upon that progress.
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